Key Points
- Kymera Therapeutics director Elena Ridloff sold 3,000 shares on May 11 at an average price of $87.00, totaling $261,000. After the sale, she still owned 3,000 shares, cutting her stake by 50%.
- This follows two earlier insider sales by Ridloff in late March and early April, when she sold 7,400 shares and 4,600 shares of Kymera stock, respectively.
- Kymera reported stronger-than-expected quarterly results, posting an EPS loss of $0.71 versus the $0.89 consensus loss and revenue of $34.37 million, well above expectations. Analysts currently rate the stock a Moderate Buy with an average price target of $118.10.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Elena Ridloff sold 3,000 shares of the company's stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $87.00, for a total transaction of $261,000.00. Following the transaction, the director owned 3,000 shares in the company, valued at $261,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Elena Ridloff also recently made the following trade(s):
- On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.37, for a total transaction of $631,738.00.
- On Wednesday, April 1st, Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.42, for a total transaction of $392,932.00.
Kymera Therapeutics Price Performance
Kymera Therapeutics stock opened at $84.10 on Tuesday. The stock has a market cap of $6.92 billion, a price-to-earnings ratio of -23.56 and a beta of 2.06. Kymera Therapeutics, Inc. has a 1 year low of $28.06 and a 1 year high of $103.00. The firm has a 50-day moving average of $83.94 and a two-hundred day moving average of $77.33.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million during the quarter, compared to analysts' expectations of $8.27 million. During the same period in the previous year, the company earned ($0.82) EPS. The firm's quarterly revenue was up 55.5% on a year-over-year basis. Research analysts expect that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.
Wall Street Analyst Weigh In
KYMR has been the subject of a number of analyst reports. Citigroup increased their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 2nd. BTIG Research cut their price objective on shares of Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. Weiss Ratings reissued a "sell (d-)" rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Finally, Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They set a "buy" rating and a $110.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $118.10.
Check Out Our Latest Research Report on Kymera Therapeutics
Hedge Funds Weigh In On Kymera Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its stake in shares of Kymera Therapeutics by 169.1% in the fourth quarter. SG Americas Securities LLC now owns 22,693 shares of the company's stock worth $1,766,000 after buying an additional 14,261 shares in the last quarter. Hudson Bay Capital Management LP lifted its stake in shares of Kymera Therapeutics by 362.7% in the third quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company's stock worth $1,309,000 after buying an additional 18,134 shares in the last quarter. Federated Hermes Inc. purchased a new position in shares of Kymera Therapeutics in the third quarter worth about $31,622,000. Candriam S.C.A. lifted its stake in shares of Kymera Therapeutics by 24.4% in the third quarter. Candriam S.C.A. now owns 191,639 shares of the company's stock worth $10,847,000 after buying an additional 37,536 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC purchased a new position in shares of Kymera Therapeutics in the third quarter worth about $1,069,000.
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
